Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD)

Biomarker Insights

Volumn 8, Issue , 2013, Pages 107-114

  Rrusso, Anthony J ^a   Pietsch, Stefanie C ^a  

^a HARTWICK COLLEGE   (United States)

Author keywords

GABA; HGF; Obsessive compulsive disorder; OCD; Symptom severity; uPA; uPAR

Indexed keywords

4 AMINOBUTYRIC ACID; SCATTER FACTOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; OBSESSIVE COMPULSIVE DISORDER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCORING SYSTEM;

EID: 84882610846     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S11931     Document Type: Article

References (51)

1. Blais MA, Smallwood P, Groves JE, Rivas-Vazquez RA. Personality and personality disorders. In: Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL, editors. Massachusetts General Hospital Comprehensive Clinical Psychiatry. 1st ed. Philadelphia, Pa: Mosby Elsevier; 2008:527-40.
2. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med. 2004;350(3):259-65.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Karno M, Golding JM. Obsessive compulsive disorder. In: Robins LN, Regier DA, editors. Psychiatric Disorders in America. New York, NY: Free Press; 1991:204-19.
5. Weissman MM, Bland RC, Canino GJ, etal. The Cross National Collaborative Group. The cross national epidemiology of obsessive compulsive disorder. J Clin Psychiatry. 1994;55(Suppl):5-10.
6. Nestadt G, Samuels JF, Romanoski AJ, etal. Obsessions and compulsions in the community. Acta Psychiatr Scand. 1994;89:219-24.
7. Nestadt G, Bienvenu OJ, Cai G, etal. Incidence of obsessive-compulsive disorder in adults. J Nerv Ment Dis. 1998;186:401-6.
8. Murray CL, Lopez AD. The Global Burden of Disease. Cambridge, MA: Harvard University Press; 1996.
9. Pittenger C, Bloch M, Wegner R, Teitelbaum C, Krystal JH, Coric V. Glutamatergic dysfunction in obsessive compulsive disorder and the potential clinical utility of glutamate-modulating agents. Prim Psychiatr. 2006;13(10):65-77.
10. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-40.
11. Bolton J, Moore GJ, MacMillan S, Stewart CM, Rosenberg DR. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry. 2001;40(8):903-6.
12. Benazon NR, Moore GJ, Rosenberg DR. Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. J Am Acad Child Adolesc Psychiatry. 2003;42(11):1279-85.
13. Smith EA, Russell A, Lorch E, etal. Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. Biol Psychiatry. 2003;54(12):1399-405.
14. Rosenberg DR, Mirza Y, Russell A, etal. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9): 1146-53.
15. Kitamura H, Shioiri T, Kimura T, Ohkubo M, Nakada T, Someya T. Parietal white matter abnormalities in obsessive-compulsive disorder: a magnetic resonance spectroscopy study at 3-Tesla. Acat Psychiatr Scand. 2006;114(2):101-8.
16. Jang JH, Kwon JS, Jang DP, etal. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Am J Psychiatry. 2006;163(7):1202-7.
17. Hall D, Dhilla A, Charalambous A, etal. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet. 2003;73:370-6.
18. Arnold PD, Rosenberg DR, Mundo E, etal. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004;174:530-8.
19. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):25-9.
20. Stewart SE, Platko J, Fagerness J, etal. A genetic family-based association study of OLIG2in obsessive-compulsive disorder. Arch Gen Psychiatry. 2007;64:209-14.
21. Heldt SA, Mou L, Ressler KJ. In vivo knockdown of GAD67in the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam in mice. Transl Psychiatry. 2012;2:e181.
22. Zachmann M, Tocci P, Nyhan WL. The occurrence of gamma-aminobutyric acid in human tissues other than brain. J Biol Chem. 1966;241:1355-8.
23. Owens DF, Kriegstein AR. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci. 2002;9:715-27.
24. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A. 1986;83:6489-93.
25. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization in hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122:1450-9.
26. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177-80.
27. Comoglio PM, Graziani A. In: Nicola NA, editor. Guidebook to Cytokines and their Receptors. Oxford, UK: Oxford University Press; 1994:182.
28. Comoglio PM, Graziani A. In Guidebook to Cytokines and their Receptors, Nicola NA, editor, Oxford University Press; 1994:185.
29. Bae MH, Bissonette GB, Mars WM, etal. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Exp Neurol. 2010;221:129-35.
30. Akimoto M, Baba A, Ikeda-Matsuo Y, etal. Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus. Neuroscience. 2004;128:155-62.
31. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27(3):157-72.
32. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region-and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci. 2003;23:622-31.
33. Levitt P, Eagleson KL, Powell EM. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci. 2004;27:400-6.
34. Powell EM, Mars WM, Levitt P. Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron. 2001;30:79-89.
35. Hirschfeld RMA. The mood disorder questionnaire: A simple, patient-rated screening instrument for bipolar disorder. Prim Care Companion J Clin Psychiatry. 2002;4:9-11.
36. Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A. 1993;90(12):5662-6.
37. Saxena S, Brody AL, Ho ML, etal. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs. major depression. Arch Gen Psychiatry. 2002;59(3):250-61.
38. Saxena S, Brody AL, Ho ML, etal. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry. 2001;50(3):159-70.
39. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry. 2003; 160(3):522-32.
40. Breiter HC, Rauch SL, Kwong KK, etal. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53(7):595-606.
41. Carlsson ML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obses-sive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(1):5-26.
42. Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand. 2000;102(6):401-13.
43. Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Mol Psychiatry. 2003;8:721-37, 715.
44. Dhossche D, Applegate H, Abraham A, etal. Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. Med Sci Monit. 2002;8:PR1-6.
45. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord. 2001;31:537-43.
46. Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand. 1993;87:312-6.
47. Simpson HB, Shungu DC, Bender J Jr, etal. Investigation of cortical glutamate-glutamine and γ-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy. Neuropsychopharmacology. 2012;37(12):2684-92.
48. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;134B(1):25-9.
49. Bohlen P, Huot S, Palfreyman MG. The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res. 1979;167:297-305.
50. Loscher W, Frey HH. Transport of GABA at the blood-CSF interface. J Neurochem. 1982;38:1072-9.
51. Uhlhaas S, Lange H, Wappenschmidt J, Olek K. Free and conjugated CSF and plasma GABA in Huntington's chorea. Acta Neurol Scand. 1986;74:261-5.